Design Therapeutics (DSGN) Capital Expenditures (2020 - 2025)

Design Therapeutics has disclosed Capital Expenditures across 6 years of filings, most recently posting $34000.0 for Q4 2025.

• Capital Expenditures for Q4 2025 came in at $34000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $121000.0 (down 44.24% YoY), and the FY2025 annual result was $193000.0, down 43.24% from the prior year.
• Capital Expenditures came in at $34000.0 for Q4 2025 at Design Therapeutics, down from $87000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $968000.0 in Q3 2021 to a low of -$16000.0 in Q3 2024.
• The 5-year median for Capital Expenditures is $88000.0 (2023), against an average of $180277.8.
• Across the five-year window, Capital Expenditures surged 2428.57% in 2021 and slumped 130.19% in 2024, its largest moves.
• Design Therapeutics' Capital Expenditures stood at $354000.0 in 2021, then slipped by 18.64% to $288000.0 in 2022, then slumped by 90.62% to $27000.0 in 2023, then plunged by 159.26% to -$16000.0 in 2024, then jumped by 312.5% to $34000.0 in 2025.
• The last three Capital Expenditures figures came in at $34000.0 (Q4 2025), $87000.0 (Q2 2025), and $72000.0 (Q1 2025), per Business Quant data.